Relapsing Polychondritis
11
4
4
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
9.1%
1 terminated out of 11 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (11)
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis
Longitudinal Study for Relapsing Polychondritis
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis
Low-dose Recombinant Human IL-2 for the Treatment of Relapsing Polychondritis
PatientSpot Formerly Known as ArthritisPower
Pediatric Relapsing Polychondritis : Diagnosis and Management in a French Retrospective Study
Single Patient Study to Treat Relapsing Polychondritis With Tocilizumab
Tocilizumab for Relapsing Polychondritis
Study on the Safety of Abatacept in Relapsing Polychondritis